Summary
Following the recent outcry in the industry over drug safety issues, the call for strategies to keep problematic drugs from reaching consumers has grown. Drug companies are being forced to reevaluate their safety investments and policies, and technology is gaining in importance in this quest. Lincoln Technologies' approach to pharmacovigilance risk management attacks the problem head-on with an approach that puts the clinical data in the forefront. With a firm handle on safety data, drug developers are free to adopt a strategic approach to pharmacovigilance, potentially lowering the risk of catastrophic safety program failures.
|